CLINICCARDS CLINICCARDS: Voxel-Based AI for 3D Dental Diagnostics
- Coordinator
- Limited Liability Company ""cliniccards"""", Ukraine
- Runs
- 1 July 2026 to 30 June 2028
- Status
- Running
- EU funding
- €499k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 101312954
What the project is doing
In the project's own words, from its summary on CORDIS.
Cliniccards AI: Deep Tech Revolution in 3D Dental DiagnosticsRadiology accounts for 82% of all diagnostic errors in medicine, with practitioners missing up to 44% of pathologies due to fatigue and physiological limitations. Manual analysis of a single 3D scan (CBCT) takes 15–20 minutes, creating a critical bottleneck amidst a global staff shortage. Furthermore, the current market is compromised by non-GDPR compliant solutions with Russian origins, creating unacceptable data security risks for EU clinics.
Cliniccards AI is the first fully GDPR-compliant ""Clean AI"" cloud platform for automated 3D segmentation and diagnostics. Unlike competitors relying on 2D projections, we utilize a True 3D Voxel-based approach (proprietary 3D CNN/U-Net architectures) to analyze volumetric data. The solution integrates seamlessly into the Cliniccards ERP ecosystem, already used by 4,700+ clinics, ensuring instant market access. Key Innovations:1.
Data Moat: We possess the largest verified private dataset in Eastern Europe (240,000 CT scans), creating an uncopyable advantage for training Deep Learning models.2. Technological Gap: We solve the ""blind spots"" of existing AI by implementing Metal Artifact Reduction (MAR) and full segmentation of nerves and sinuses directly in voxel space.3. Digital Sovereignty: We provide a secure European alternative, ensuring data never leaves safe jurisdictions.
Measurable Objectives (TRL 4 → TRL 7) Over 24 months, we aim to achieve:- Diagnostic Excellence: Sensitivity >97.3% for pathologies and >95% segmentation accuracy (IoU) for critical anatomy.- Efficiency: Reducing analysis time from 20 minutes to 2–5 seconds (150x faster).- Commercial Impact: Validating a >20% increase in Case Acceptance Rates via pilot testing and securing MDR Class IIa readiness. Action Plan The project involves finalizing R&D (specifically for artifact reduction), conducting a 3-phase ""Living Lab"" clinical trial in 50 clinics, and filing 4 patent applications""
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Limited Liability Company ""cliniccards"""" | Kyiv | Ukraine | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI